Efficacy and Safety of Alendronate in Chinese Children or Adolescents With Osteogenesis Imperfecta
Efficacy and Safety of Alendronate in Chinese Children or Adolescents With Osteogenesis Imperfecta
Alendronate should be considered as an alternative therapy of osteogenesis imperfecta (OI)
 because it significantly increased areal bone mineral density (BMD) and its Z score,
 decreased fracture incidence, inhibited bone resorption biomarkers. Alendronate exerted
 beneficial roles in different age brackets, especially in young patients with OI.
Inclusion Criteria:

 1. children or adolescents aged 0-18 years,

 2. had either a history of at least once minor-impact fracture or age and sex adjusted
 areal BMD Z score of -1.0 or less at lumbar spine or total hip;

 3. with or without blue sclera, impaired hearing, joint hypermobility or dentinogenesis
 imperfecta;

 4. with or without slim long bone; with or without cranial epactal bones, signs of
 multiple fractures, bony deformity in skeletal X-ray films.

 Exclusion Criteria:

 1. previous history of rickets, hyperparathyroidism, other metabolic or inherited bone
 diseases; malignant disease; coeliac disease; hyperthyroidism;

 2. therapy history of BPs within recent two years; severe renal failure (creatinine
 clearance <40 ml/min), chronic liver disease; severe diseases of gastrointestinal
 tract;

 3. unable to keep upright for at least 30 minutes daily .